EOLS News and Press, Evolus Inc. From 12/12/23

2023-12-12 10:33:17 ET More on AbbVie, Evolus, etc. AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time AbbVie: $10 Billion Cancer Deal To Boost Growth AbbVie upgraded at Goldman ...

2023-12-05 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-08 10:00:55 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector as earnings close in For further details see: Durect, Lumos Pharma among healthcare movers

2023-11-07 20:45:25 ET Evolus, Inc. (EOLS) Q3 2023 Earnings Conference Call November 07, 2023, 16:30 ET Company Participants Ned Mitchell - IR Rui Avelar - Chief Medical Officer & Head, Research & Development David Moatazedi - President, CEO & Directo...

2023-11-07 16:41:41 ET More on Evolus Evolus: Gaining Market Share Needham says Abbvie's Botox sales results good news for Evolus, Revance Seeking Alpha’s Quant Rating on Evolus Historical earnings data for Evolus Financial information for Evol...

Record Quarterly Net Revenue of $50 Million for Q3 2023, Up 48% from Q3 2022 Raises Full-Year 2023 Net Revenue Guidance from $185 to $195 Million to $194 to $198 Million Operating Use of Cash in Q3 of $0.9 Million, Demonstrating Continued Progress Towards Achieving Profitability ...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

Evolus Inc. (EOLS) is expected to report $-0.25 for Q3 2023

“Extra-strength” 40U formulation demonstrated a duration of 26 weeks, or 6 months, when measuring the time for a patient to return back to their baseline Glabellar Line score after a single treatment 40U results indicate a similar safety profile to lower dose arms in the stu...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will present at the following investment conferences in November. Audio webcasts of these events will be available ...